Free tool
FDA Approval Tracker
Last checked: Nov 20, 2026Latest source record: Dec 16, 2025Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
6
2023 to 2026
Breakthrough
3
Accelerated
0
Priority review
4
Orphan
3
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2023 | 0 | 0 |
| 2024 | 2 | 1 |
| 2025 | 2 | 1 |
| 2026 | 0 | 0 |
6 approvals
Newest first. Hover a badge for what it means.
- Exdensur (Depemokimab-Ulaa) · Glaxosmithkline LLCDec 16, 2025
To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapy
- Jascayd (Nerandomilast) · Boehringer IngelheimOct 7, 2025
To treat idiopathic pulmonary fibrosis
- Brinsupri (Brensocatib) · Insmed INCAug 12, 2025
To treat non-cystic fibrosis bronchiectasis
- Alyftrek (Deutivacaftor, Tezacaftor, Vanzacaftor Calcium) · Vertex Pharms INCDec 20, 2024
For the treatment of cystic fibrosis (CF) in patients 6 years of age and older
- Ohtuvayre (Ensifentrine) · MsdJun 26, 2024
To treat chronic obstructive pulmonary disease
- Winrevair (Sotatercept-Csrk) · Merck Sharp DohmeMar 26, 2024
To treat pulmonary arterial hypertension
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.